Research Paper Volume 13, Issue 8 pp 11336—11351

Figure 6. The role of p38 in mediating the effect of COX-2 and/or TGF-β1 on enhancing the osteogenic potential of BMP9 in MSCs. (A) Western blotting shows that the levels of p38 and p-p38 were affected by BMP9 and/or COX-2. (B) Quantification of western blots shows that the level of p38 and p-p38 was affected by BMP9 and/or COX-2. (C) Western blotting shows that the level of p38 and p-p38 was affected by LY364947, COX-2, and/or BMP9. (D) Quantification results of western blots assay shows that the level of p38 and p-p38 was affected by LY364947, COX-2, and BMP9. (E) Western blotting shows the potential effect of BMP9, TGF-β1, and/or SB203580 on Runx2. (F) Quantification results of western blots shows the level of Runx2 was affected by BMP9, TGF-β1, and/or SB203580. (G) Alizarin Red S staining shows that the mineralization was affected by BMP9, TGF-β1, and/or SB203580 (day 20). (H) Quantification results of Alizarin Red S assay shows that mineralization was affected by BMP9, TGF-β1, and/or SB203580. SB203580: p38 MAPK specific inhibitor; LY364947: TGF-βRI specific inhibitor. ^“**”p < 0.01, ^“#”p < 0.05, and ^“##”p < 0.01.